NewsNovo

FDA alignment gives CVKD's CAD-1005 a cleaner Phase 3 path, but the proof is still ahead

8/31/2026

The regulatory path for Cadrenal Therapeutics (Nasdaq: CVKD) got materially cleaner on August 31, when the company disclosed a positive outcome from a Type D Meeting with the FDA held July 28, 2026.

FDA and Cadrenal aligned on both the primary endpoint definition and the blinding protocol for the Phase 3 registrational study of CAD-1005, a first-in-class 12-lipoxygenase (12-LOX) inhibitor targeting heparin-induced thrombocytopenia.

The case for the stock here is regulatory de-risking; the complication is that a $2 billion peak annual revenue figure the company projects remains entirely conditional on a trial that has yet to begin dosing patients.

Heparin-induced thrombocytopenia affects approximately 50,000 patients with confirmed acute diagnoses annually in the United States, according to Cadrenal.